An injectable weekly medicine mimicking three metabolic hormones at once, producing the largest weight loss yet seen from a drug alongside major improvements in liver fat, blood sugar, blood pressure, and blood fats. The evidence is impressive but early and largely maker-funded. Main downsides are stomach upset, faster heart rate, and muscle loss. Not yet approved. (Full Review)

Protocol

Administration

Once-weekly injection

Subcutaneous; single weekly dose, not split

Dose

2 mg start, escalate to 4–12 mg

Gradual escalation over weeks; higher doses, greater effect and side effects

Timing

Same day each week

Hour not critical; with or without food

Time to effect

Peak weight loss

48–68 weeks

Meaningful weight and metabolic changes accrue over months

Liver fat reduction

24 weeks

Dramatic liver-fat drops measured at this endpoint

Appetite suppression

First weeks

Early weight loss typically begins within the first weeks of dosing

Benefits

High: Substantial body-weight and fat-mass reduction; liver fat reduction; improved blood sugar control

Medium: Blood pressure reduction; improved blood lipid profile

Low: Reduced osteoarthritis knee pain; obstructive sleep apnea improvement

Speculative: Broad longevity and healthspan signals; reduced alcohol and appetitive behavior

Contraindications

Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2

Prior serious hypersensitivity reaction

Pregnancy and breastfeeding

Active pancreatitis

Severe gastrointestinal motility disorders (gastroparesis)

Key Interactions

Insulin and insulin-secreting drugs (sulfonylureas such as glipizide, glyburide)

Other glucose-lowering or weight-loss agents (GLP-1 agonists, SGLT2 inhibitors such as empagliflozin, other incretins)

Oral medications with narrow dosing windows

Glucose-lowering supplements (berberine, high-dose cinnamon, alpha-lipoic acid)

Risk & Side Effects

High: Gastrointestinal adverse events; dose-dependent heart rate increase

Medium: Loss of lean muscle mass; reactive increases in blood sugar or impaired glucose handling

Low: Injection-site and hypersensitivity reactions; pancreatitis and gallbladder events

Speculative: Thyroid C-cell tumor signal; effects on bone density

Monitoring

Marker	Target	Why
HbA1c	4.8–5.4%	Tracks average blood sugar and glucose benefit
Fasting glucose	75–90 mg/dL	Detects glucose lowering and hypoglycemia risk
Resting heart rate	55–70 bpm	Monitors the drug's known heart-rate rise
ALT / liver enzymes	ALT <25 U/L (men), <20 U/L (women)	Tracks liver-fat improvement and liver safety
Lipid panel (LDL, triglycerides, HDL)	LDL <100 mg/dL; triglycerides <100 mg/dL; HDL >50 mg/dL	Captures cardiovascular-risk improvement
Blood pressure	<120/80 mmHg	Monitors the blood-pressure-lowering benefit
Lean body mass / body composition	Stable or minimal decline	Detects muscle loss during weight reduction
Vitamin D (25-OH)	40–60 ng/mL	Supports bone health during rapid weight loss

Cadence: Baseline, then at roughly 4–12 weeks during titration, and every 3–6 months thereafter.

Qualitative Assessment

Energy levels and daily stamina
Appetite and satiety changes
Strength and physical performance (a proxy for preserved muscle)
Sleep quality (especially snoring or apnea symptoms)
Gastrointestinal comfort during and after titration

Retatrutide for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment